Reference Publications

Relevant News Links to Worldwide Problem of Antibiotic Resistant Infection


WHO Warning Antibiotic Resistant Infections


WHO Warns 10 Million Deaths From Antibiotic Resistant Infections


Superbug Crisis Already Here

Current National and Health Security


Antibiotic Resistant Infection Threat to National Security


Bill Gates on Antibiotic Resistant Infection Threat

DIBI Technology Publications

Anti-infective- Core to CPI Mission (path to human clinical trials) 

Iron Sequestrant DIBI, a Potential Alternative for Nares Decolonization of Methicillin-Resistant Staphylococcus aureus, is Anti-infective and Inhibitory for Mupirocin-Resistant Isolates. Allan DS, Parquet MDC, Savage KA, Holbein BE. Antimicrob Agents Chemother 64:e02353-19.


Antibiotic resistant Acinetobacter baumannii  is susceptible to the novel iron-sequestering anti-infective DIBI in vitro and in experimental pneumonia in mice. Parquet MDC, Savage KA, Allan DS, Ang MTC, Chen W, Logan SM, Holbein BE. Antimicrob Agents Chemother.


Novel Iron-Chelator DIBI Inhibits Staphylococcus aureus Growth

Suppresses Experimental MRSA Infection in Mice and Enhances the Activities of Diverse Antibiotics in vitro. Parquet MDC, Savage KA, Allan DS, Davidson RJ, Holbein BE. Front Microbiol.


Effect of trace iron levels and iron withdrawal 

by chelation on the growth of Candida albicans and Candida vini. Holbein BE, Mira de Orduña R.
FEMS Microbiol Lett.


Potential Mechanisms of Mucin-Enhanced Acinetobacter baumannii Virulence

in the Mouse Model of Intraperitoneal Infection. Harris G, Holbein BE, Zhou H, Xu HH, Chen W.

Infect Immun 87:e00591-19.


Iron should be restricted in acute infection

Scott CR, Holbein BE, Lehmann CD. Frontiers in Bioscience, Landmark, 25, 673-682, 2020Antimicrob Agents Chemother.


DIBI, a 3-hydroxypyridin-4-one chelator iron-binding polymer with enhanced antimicrobial activity.

Ang MTC, Gumbau-Brisa R, Allan DS, McDonald R, Ferguson MJ, Holbein BE, Bierenstiel M. Medchemcomm. 


Exploiting the Achilles’ heel of iron dependence 

in antibiotic resistant bacteria with new anti-microbial iron withdrawal agents. Holbein BE, Ang MTC, Allan DS, Chen W, Lehmann C. “Mitigation of Antimicrobial Resistance’’ Springer Nature (invited review, in press)

Read More

Collaborator-led Complementary studies  (re platform aspects of CPI technology) 

DIBI, a novel 3-hydroxypyridin-4-one chelator iron-binding polymer, inhibits breast cancer cell growth and functions as a chemosensitizer by promoting S-phase DNA damage Greenshields AL, Power Coombs MR, Fernando W, Holbein BE, Hoskin DW. Biometals

Anti-inflammatory effects of a novel iron chelator, DIBI, in experimental sepsis.
Thorburn T, Aali M, Kostek L, LeTourneau-Paci C, Colp P, Zhou J, Holbein B, Hoskin D, Lehmann C. Clin Hemorheol Microcirc.


Iron chelation for the treatment of uveitis.

Chen J, Zhou J, Kelly M, Holbein BE, Lehmann C. Med Hypotheses. 2017. 


The utility of iron chelators in the management of inflammatory disorders.

Lehmann C, Islam S, Jarosch S, Zhou J, Hoskin D, Greenshields A, Al-Banna N, Sharawy N, Sczcesniak A, Kelly M, Wafa K, Cheliak W, Holbein B.
Mediators Inflamm. 2015.


Anti-inflammatory and anti-bacterial effects 

of iron chelation in experimental sepsis.
Islam S, Jarosch S, Zhou J, Parquet Mdel C, Toguri JT, Colp P, Holbein BE, Lehmann C. J Surg Res.2016.  


Iron Chelation as Novel Treatment for Interstitial Cystitis.

Hagn G, Westhofen R, Burkovskiy I, Holbein B, Zhou J, Lehmann C. Pharmacology. 2019. 


Inhibitory effect of iron withdrawal 

by chelation on the growth of human and murine mammary carcinoma and fibrosarcoma cells.
Power Coombs MR, Grant T, Greenshields AL, Arsenault DJ, Holbein BE, Hoskin DW. Exp Mol Pathol. 2015. 


Selective sensitivity of the gut microbiome 

to iron chelators in polybacterial abdominal sepsis. Dickson K, Liu S, Zhou J, Langille M, Holbein BE, Lehmann C.
Med Hypotheses. 2018.